Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 3Inflammation 2Glioblastoma 2Frailty 2Recurrence 1Polycystic Ovary Syndrome 1Obesity 1Neoplasms 1Neoplasm Metastasis 1Myofibroma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hemorrhage 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anemia 1Adenomyosis 1Adenocarcinoma 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 34Standard of Care 32Carboplatin 32Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Cisplatin 24Gemcitabine 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 18Docetaxel 18Rituximab 16Irinotecan 16Cetuximab 16Drug Therapy 15Doxorubicin 15dostarlimab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13Prednisone 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Ascorbic Acid × 1 year × Clear all
NCT07476443 2026-03-17

VitC-CoQ10

Ain Shams University

Phase 2/3 Not yet recruiting
75 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡